Hematology

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(Constellation) CPI-0610-02 / MANIFEST studyA Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis)Leber, Dr BrianOpen to recruitmentNCT02158858
(GlycoMimetics) GMI-1271-301A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid LeukemiaKhalaf, Dr DinaOpen to recruitmentNCT03616470
(Horizon Health Network) The M4 Study The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Cohort Study (The M4 Study) Kouroukis, Dr TomOpen to recruitmentNCT03421132
(McMaster) CTTC 1901 / OZM-099A Randomized Pilot Trial comparing Anti-Thymocyte Globulin (ATG) with ATG plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT)Walker, Dr IrwinOpen to recruitmentNCT04202835
(Novartis) CCTL019B2302A Phase IIIb Study of the Safety and Efficacy of Tisagenlecleucel Out of Specification for Commercial Release in Patients Who Are Consistent With the Label IndicationKouroukis, Dr TomOpen to recruitmentNCT04094311
(Sierra Oncology) SRA-MMB-301 / MOMENTUMA Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor TherapyHillis, Dr ChristopherOpen to recruitmentNCT04173494
(UHN) CFI-400945-CL-002An Open-Label, Dose Escalation, Safety and Pharmacokinetic Study of CFI-400945 Fumarate Administered Orally to Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeLeber, Dr BrianOpen to recruitmentNCT03187288
CMRG 007 / MCRN 007 / ALGONQUINA Phase 1/2 Multi-Center, Open Label, Dose Escalation Study to Determine the Recommended Phase 2 Dose, Safety and Efficacy of the Antibody Drug Conjugate GSK2857916 in Combination with Pomalidomide and Low-Dose Dexamethasone in Subjects with Relapsed and/or Refractory Multiple Myeloma (MM)Kouroukis, Dr TomOpen to recruitmentNCT03715478
(CCTG) LY.17A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell LymphomaFraser, Dr GraemeRecruitment on hold - COVID-19NCT02436707
(Celgene) ACE-536-MDS-002 / COMMANDSA Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell TransfusionsLeber, Dr BrianRecruitment on hold - COVID-19NCT03682536
(AbbVie) M16-191A Randomized, Open-Label, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib Alone In Subjects With MyelofibrosisLeber, Dr BrianSuspended/On holdNCT04472598
(AbbVie) M20-178 / TRANSFORM-2A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in
Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory
Myelofibrosis (TRANSFORM-2)
Leber, Dr BrianSuspended/On holdNCT04468984
Download PDF